 - For T2DM participants receiving any of the following medications within 7 days of study participation: 1. Other SGLT2 inhibitors eg, dapagliflozin, canagliflozin, empagliflozin; 2. Other injectable anti-hyperglycemic agents including pramlintide or Glucagon-like peptide-1 GLP-1 analogues; 3. Any immunosuppressive drugs, including cyclosporine, tacrolimus, sirolimus; 4. Oral corticosteroids note that inhaled, nasal and topical corticosteroids are permitted; 5. Any potent drug-metabolizing enzyme-inducing drug, including rifampin, phenytoin, and carbamazepine; 6. Probenecid, valproic acid, gemfibrozil. 